WALTHAM, Massachusetts, October 21 /PRNewswire/ --
- Ofatumumab Will Garner Impressive Sales But Will Not Take Significant Patient Share from Rituxan/MabThera, According to a New Report from Decision Resources
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2017, robust 3.6 percent annual growth in the non-Hodgkin's lymphoma drug market will be driven by increasing market penetration of Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan/Roche's MabThera, particularly in the chronic lymphocytic leukemia market.